Karyopharm Therapeutics (KPTI) director receives 15,508 RSUs in equity award

Q: What did Karyopharm Therapeutics (KPTI) director Su Zhen report on this Form 4?

Director Su Zhen reported receiving a grant of 15,508 restricted stock units (RSUs) of Karyopharm Therapeutics common stock. This was a compensation-related award, not an open-market stock purchase or sale, and is recorded as a direct ownership position.

Q: How many KPTI shares or RSUs does Su Zhen hold after this transaction?

After the reported grant, Su Zhen holds 15,508 Karyopharm Therapeutics common shares/RSUs directly. This entire amount comes from the awarded restricted stock units reported in this Form 4, with no additional derivative positions shown in the filing excerpt.

Q: What are the vesting terms of Su Zhen’s RSU award at Karyopharm Therapeutics (KPTI)?

The 15,508 RSUs awarded to Su Zhen vest 100% on May 21, 2027 . RSUs convert into Karyopharm common stock on a one-for-one basis, meaning each RSU becomes one share once it is vested and delivered under the plan’s terms.

Q: When will the shares from Su Zhen’s KPTI RSUs actually be delivered?

Although the RSUs vest on May 21, 2027 , delivery of the underlying shares is deferred. Shares are delivered at the earlier of the director’s separation from service with Karyopharm Therapeutics or a change-in-control event , according to the award’s footnote.

Q: Under which plan were Su Zhen’s KPTI RSUs granted and what is the conversion rate?

The RSUs were granted under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended . The footnote states that the RSUs convert into Karyopharm common stock on a one-for-one basis , so each RSU will become one share when delivered.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Su Zhen reported acquisition or exercise transactions in this Form 4 filing.

Karyopharm Therapeutics Inc. director Su Zhen received a grant of 15,508 restricted stock units (RSUs) of common stock as equity compensation. The RSUs vest 100% on May 21, 2027, and delivery of the underlying shares is deferred until separation from service or a change-in-control event. Following this award, Su Zhen directly holds 15,508 shares/RSUs in total.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Su Zhen

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,508	$0.00	--

Holdings After Transaction: Common Stock — 15,508 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 15,508 RSUs Price per share: $0.00 per share Shares/RSUs held after grant: 15,508 shares +1 more

4 metrics

RSUs granted 15,508 RSUs Grant of restricted stock units to director Su Zhen

Price per share $0.00 per share Compensation grant, not open-market purchase

Shares/RSUs held after grant 15,508 shares Total direct holdings following the reported transaction

Vesting date May 21, 2027 RSUs vest 100% on this date

Key Terms

restricted stock units (RSUs), 2022 Equity Incentive Plan, convert into common stock on a one-for-one basis, change-in-control event, +1 more

5 terms

restricted stock units (RSUs) financial

"Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

2022 Equity Incentive Plan financial

"pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended."

convert into common stock on a one-for-one basis financial

"RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis."

change-in-control event financial

"delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service ... and (b) a change-in-control event."

separation from service financial

"delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service ... and (b) a change-in-control event."

Form 4 Insider Transactions: What Each Field Means →

05/26/2026 - 04:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Su Zhen

(Last)

(First)

(Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON

MASSACHUSETTS

02459

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/21/2026		A		15,508⁽¹⁾	A	$0	15,508	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.

	/s/ Nancy Smith, Attorney-in-Fact for Zhen Su	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Karyopharm Therapeutics (KPTI) director Su Zhen report on this Form 4?

Director Su Zhen reported receiving a grant of 15,508 restricted stock units (RSUs) of Karyopharm Therapeutics common stock. This was a compensation-related award, not an open-market stock purchase or sale, and is recorded as a direct ownership position.

How many KPTI shares or RSUs does Su Zhen hold after this transaction?

After the reported grant, Su Zhen holds 15,508 Karyopharm Therapeutics common shares/RSUs directly. This entire amount comes from the awarded restricted stock units reported in this Form 4, with no additional derivative positions shown in the filing excerpt.

What are the vesting terms of Su Zhen’s RSU award at Karyopharm Therapeutics (KPTI)?

The 15,508 RSUs awarded to Su Zhen vest 100% on May 21, 2027. RSUs convert into Karyopharm common stock on a one-for-one basis, meaning each RSU becomes one share once it is vested and delivered under the plan’s terms.

When will the shares from Su Zhen’s KPTI RSUs actually be delivered?

Although the RSUs vest on May 21, 2027, delivery of the underlying shares is deferred. Shares are delivered at the earlier of the director’s separation from service with Karyopharm Therapeutics or a change-in-control event, according to the award’s footnote.

Under which plan were Su Zhen’s KPTI RSUs granted and what is the conversion rate?

The RSUs were granted under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. The footnote states that the RSUs convert into Karyopharm common stock on a one-for-one basis, so each RSU will become one share when delivered.